News | July 04, 2023
Adare Pharma divests Adare Biome to dsm-firmenich
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated
